A new AI-driven clinical monitoring approach aims to identify uncertainty about whether cancer patients will respond to therapy. The report focuses on metastatic non-small cell lung cancer and first-line chemoimmunotherapy, where outcomes can diverge sharply across patients, leaving some with substantial toxicity but limited benefit.